Navigation Links
Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinson's Disease Research
Date:1/6/2009

NEW YORK, Jan. 6 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation awarded a total of about $2.7 million to four industry research teams for pre-clinical research on potential new treatments for Parkinson's disease.

The funding was awarded under the Foundation's Therapeutics Development Initiative. This program, first launched in 2006, supports and bolsters industry-focused efforts on Parkinson's research. TDI is part of MJFF's focus on 'de-risking' preclinical PD research for biotech and pharmaceutical companies, thus expanding and catalyzing industry investments in Parkinson's drug development. By adding MJFF resources to companies' own, the Foundation aims to make Parkinson's therapies a more attractive bet and help to push research further along the pipeline.

The funded projects are listed below. Full information, including grant abstracts and researcher bios, is available on the Foundation's Web site -- www.michaeljfox.org.

Cerebrospinal Fluid (CSF) Biomarkers of Microtubule-mediated Axonal Transport for Monitoring of Disease Progression and Therapeutics Interventions in Parkinson's Disease

Patrizia Fanara, Ph.D., KineMed, Inc.

Selective Inhibition of Cyclic Nucleotide Phosphodiesterase Type 7 (PDE7): A Novel and Efficacious Approach to Treating Parkinson's Disease

Vincent Allen Florio, Ph.D., Omeros Corporation

Development of ER-beta Agonists for the Treatment of Parkinson's Disease

Roger Olsson, Ph.D., and Krista McFarland, Ph.D., Acadia Pharmaceuticals, Inc.

Multiphosphatase Inhibitors as Therapeutics for Parkinson's Disease

Arnon Rosenthal, Ph.D., and Franz F. Hefti, Ph.D., ShanaRX

About The Michael J. Fox Foundation

Founded in 2000, The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease within the decade through an aggressively funded research agenda. The Foundation has funded over $130 million in research to date.


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
2. Michael J. Fox Foundation Commits Up to $3 Million for Clinical Trials That Can Improve Treatment of Parkinsons Disease
3. New Michael J. Fox Foundation Initiative Will Drive Development of Web-Based Tools to Increase Patient Participation in Parkinsons Clinical Trials
4. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
5. Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine
6. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
7. Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinsons Disease
8. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
9. Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee
10. Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinsons Disease Under Rapid Response Innovation Awards 2008
11. Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... janvier 2017  ResMed (NYSE : RMD), BMC (Pékin, Chine) ... annoncé aujourd,hui qu,ils se sont mis d,accord sur le ... parties. BMC et 3B seront autorisés à vendre leurs ... ResMed, et ResMed effectuera le paiement de la décision ... litige de Floride entre les deux parties. Le règlement ...
(Date:1/23/2017)... 2017 NeuroVive Pharmaceutical AB (Nasdaq Stockholm: ... preclinical collaboration agreement with the Children,s Hospital of ... M.D., a US key opinion leader in the mitochondrial medicine ... ... from NeuroVive,s research program, NVP015, in certain experimental disease models. ...
(Date:1/22/2017)... DAVOS, Switzerland and ABU DHABI , ... leaders from the US ... , Hospital of the Future , at ... in the hospital of the future will be driven by big data and ... better," according to the panel of experts that discussed the ,Hospital of the ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... January 23, 2017 , ... "ProRandom is a set of camera tools that allow video ... in Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... of text with video footage. ProRandom works by using a virtual camera to create ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... Society of Anesthesiologists® (ASA®), the Foundation for Anesthesia Education and Research (FAER), ... (AAOS) and the Cigna Foundation, encourages proposals supporting high quality research using ...
(Date:1/23/2017)... ... ... a story of love and redemption, hope and uncertainty as a girl makes her way ... at the Mill” is the creation of published author, Lois Kulp, who was born in ... County on Crow Hill. The inn, the mill and "Post Yokel" are within ...
(Date:1/23/2017)... , ... January 23, 2017 ... ... (SNP) has launched online education programs and resources at seafoodnutrition.org/programs and seafoodnutrition.org/resources ... benefits of a seafood-rich diet. These resources have been developed for use ...
(Date:1/23/2017)... ... ... “Some Infallible Characteristics of Christ”: a fascinating and entrancing novel exploring the gifts ... published author, Rev. Dr. Robert W. Thomas, the third of seven siblings. He was ... a pastor for over fifteen years. He is a graduate of N.C. College of ...
Breaking Medicine News(10 mins):